EMEA-002183-PIP01-17-M01
Key facts
Invented name |
Idefirix
|
Active substance |
Imlifidase
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0076/2022
|
PIP number |
EMEA-002183-PIP01-17-M01
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Prevention of graft rejection following solid organ transplantation
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Hansa Biopharma AB
E-mail: info@hansabiopharma.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|